How many times has a patient heard “I got it all out,” only to learn a week later that malignant tumor was left behind? Breast-conserving therapy like lumpectomy, for example, results in positive margins (that is, tumor left behind) in 20-30% of cases, even today in the USA. The reason for this is that tumors blend into nearby tissue, and the human eye has a difficult time discriminating malignant tissue from normal tissue, even after decades of experience.
Curadel is trying hard to improve human surgery in general, and cancer surgery in particular. We have already developed new FLARE® NIR fluorescent contrast agents (drugs) that “light up” tumors, blood vessels, nerves, lymph nodes, and ureters after a single, low-dose injection. Our FLARE® imaging systems can even see two of these FLARE® contrast agents at the same time, permitting surgeons to “mix and match” agents as needed for better patient outcome.
Over the next decade, these new FLARE® contrast agents will be moving through the long, laborious regulatory process so that they become available to patients worldwide. Please Join our Mailing List to be kept in the loop or Contact Us with any questions.